Detection of culture-negative sepsis in clinical blood samples using a microfluidic assay for combined CD64 and CD69 cell capture

Yun Zhou, Ye Zhang, Amanda Johnson, Amanda Venable, John Griswold, Dimitri Pappas

Research output: Contribution to journalArticle

Abstract

Sepsis is a life-threatening disease that affects millions of people every year. Rapid detection of sepsis assists clinicians to initiate timely antibiotic therapy and to reduce mortality. At the same time, accurate point-of-care detection is needed to reduce unnecessary use of antibiotics. One of the principal challenges in sepsis diagnosis is that many sepsis cases do not result in positive blood cultures. These so-called culture-negative cases present a significant health threat. In this work, we present a microfluidic cells separation system for the detection of sepsis in both culture-positive and culture-negative cases. Leukocytes were captured in several affinity separation zones of a microchip based on CD64, CD69, and CD25 expression. To validate this assay 40 septic patients and 10 healthy volunteers were enrolled in this study. Septic patients were divided into culture-positive (n = 12) and culture-negative cases (n = 21). CD64 + cell capture demonstrated excellent accuracy for sepsis detection with an area under the receiver operating characteristic curves (AUC) of 0.962. A combined panel of CD64 + and CD69 + cell counts was constructed, and the new panel outperformed each of these two biomarkers alone with the AUC of 0.978. Our affinity microfluidic devices were validated by conventional flow cytometry analysis. Results showed that the cell capture number of specific affinity region increased along with the increase of its corresponding antigen expression. This clinical validation confirms that CD64 and CD69 cell separations are a powerful sepsis assay with the potential for point-of-care analysis in culture-positive and culture-negative cases.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalAnalytica Chimica Acta
Volume1062
DOIs
StatePublished - Jul 25 2019

Fingerprint

Microfluidics
Assays
Sepsis
Blood
blood
assay
Anti-Bacterial Agents
Point-of-Care Systems
Flow cytometry
Biomarkers
Cell Separation
Lab-On-A-Chip Devices
antibiotics
Area Under Curve
Health
Cell Count
Antigens
flow cytometry
detection
antigen

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry
  • Environmental Chemistry
  • Spectroscopy

Cite this

Zhou, Yun ; Zhang, Ye ; Johnson, Amanda ; Venable, Amanda ; Griswold, John ; Pappas, Dimitri. / Detection of culture-negative sepsis in clinical blood samples using a microfluidic assay for combined CD64 and CD69 cell capture. In: Analytica Chimica Acta. 2019 ; Vol. 1062. pp. 110-117.
@article{99f66be7d97747418ca7aaa644a6616b,
title = "Detection of culture-negative sepsis in clinical blood samples using a microfluidic assay for combined CD64 and CD69 cell capture",
abstract = "Sepsis is a life-threatening disease that affects millions of people every year. Rapid detection of sepsis assists clinicians to initiate timely antibiotic therapy and to reduce mortality. At the same time, accurate point-of-care detection is needed to reduce unnecessary use of antibiotics. One of the principal challenges in sepsis diagnosis is that many sepsis cases do not result in positive blood cultures. These so-called culture-negative cases present a significant health threat. In this work, we present a microfluidic cells separation system for the detection of sepsis in both culture-positive and culture-negative cases. Leukocytes were captured in several affinity separation zones of a microchip based on CD64, CD69, and CD25 expression. To validate this assay 40 septic patients and 10 healthy volunteers were enrolled in this study. Septic patients were divided into culture-positive (n = 12) and culture-negative cases (n = 21). CD64 + cell capture demonstrated excellent accuracy for sepsis detection with an area under the receiver operating characteristic curves (AUC) of 0.962. A combined panel of CD64 + and CD69 + cell counts was constructed, and the new panel outperformed each of these two biomarkers alone with the AUC of 0.978. Our affinity microfluidic devices were validated by conventional flow cytometry analysis. Results showed that the cell capture number of specific affinity region increased along with the increase of its corresponding antigen expression. This clinical validation confirms that CD64 and CD69 cell separations are a powerful sepsis assay with the potential for point-of-care analysis in culture-positive and culture-negative cases.",
author = "Yun Zhou and Ye Zhang and Amanda Johnson and Amanda Venable and John Griswold and Dimitri Pappas",
year = "2019",
month = "7",
day = "25",
doi = "10.1016/j.aca.2019.02.039",
language = "English (US)",
volume = "1062",
pages = "110--117",
journal = "Analytica Chimica Acta",
issn = "0003-2670",
publisher = "Elsevier",

}

Detection of culture-negative sepsis in clinical blood samples using a microfluidic assay for combined CD64 and CD69 cell capture. / Zhou, Yun; Zhang, Ye; Johnson, Amanda; Venable, Amanda; Griswold, John; Pappas, Dimitri.

In: Analytica Chimica Acta, Vol. 1062, 25.07.2019, p. 110-117.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of culture-negative sepsis in clinical blood samples using a microfluidic assay for combined CD64 and CD69 cell capture

AU - Zhou, Yun

AU - Zhang, Ye

AU - Johnson, Amanda

AU - Venable, Amanda

AU - Griswold, John

AU - Pappas, Dimitri

PY - 2019/7/25

Y1 - 2019/7/25

N2 - Sepsis is a life-threatening disease that affects millions of people every year. Rapid detection of sepsis assists clinicians to initiate timely antibiotic therapy and to reduce mortality. At the same time, accurate point-of-care detection is needed to reduce unnecessary use of antibiotics. One of the principal challenges in sepsis diagnosis is that many sepsis cases do not result in positive blood cultures. These so-called culture-negative cases present a significant health threat. In this work, we present a microfluidic cells separation system for the detection of sepsis in both culture-positive and culture-negative cases. Leukocytes were captured in several affinity separation zones of a microchip based on CD64, CD69, and CD25 expression. To validate this assay 40 septic patients and 10 healthy volunteers were enrolled in this study. Septic patients were divided into culture-positive (n = 12) and culture-negative cases (n = 21). CD64 + cell capture demonstrated excellent accuracy for sepsis detection with an area under the receiver operating characteristic curves (AUC) of 0.962. A combined panel of CD64 + and CD69 + cell counts was constructed, and the new panel outperformed each of these two biomarkers alone with the AUC of 0.978. Our affinity microfluidic devices were validated by conventional flow cytometry analysis. Results showed that the cell capture number of specific affinity region increased along with the increase of its corresponding antigen expression. This clinical validation confirms that CD64 and CD69 cell separations are a powerful sepsis assay with the potential for point-of-care analysis in culture-positive and culture-negative cases.

AB - Sepsis is a life-threatening disease that affects millions of people every year. Rapid detection of sepsis assists clinicians to initiate timely antibiotic therapy and to reduce mortality. At the same time, accurate point-of-care detection is needed to reduce unnecessary use of antibiotics. One of the principal challenges in sepsis diagnosis is that many sepsis cases do not result in positive blood cultures. These so-called culture-negative cases present a significant health threat. In this work, we present a microfluidic cells separation system for the detection of sepsis in both culture-positive and culture-negative cases. Leukocytes were captured in several affinity separation zones of a microchip based on CD64, CD69, and CD25 expression. To validate this assay 40 septic patients and 10 healthy volunteers were enrolled in this study. Septic patients were divided into culture-positive (n = 12) and culture-negative cases (n = 21). CD64 + cell capture demonstrated excellent accuracy for sepsis detection with an area under the receiver operating characteristic curves (AUC) of 0.962. A combined panel of CD64 + and CD69 + cell counts was constructed, and the new panel outperformed each of these two biomarkers alone with the AUC of 0.978. Our affinity microfluidic devices were validated by conventional flow cytometry analysis. Results showed that the cell capture number of specific affinity region increased along with the increase of its corresponding antigen expression. This clinical validation confirms that CD64 and CD69 cell separations are a powerful sepsis assay with the potential for point-of-care analysis in culture-positive and culture-negative cases.

UR - http://www.scopus.com/inward/record.url?scp=85062474916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062474916&partnerID=8YFLogxK

U2 - 10.1016/j.aca.2019.02.039

DO - 10.1016/j.aca.2019.02.039

M3 - Article

C2 - 30947986

AN - SCOPUS:85062474916

VL - 1062

SP - 110

EP - 117

JO - Analytica Chimica Acta

JF - Analytica Chimica Acta

SN - 0003-2670

ER -